{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-026877","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.919566+00:00","generated_at":"2026-06-05T02:54:54.161346+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Candel accelerates unveiling of second enLIGHTEN candidate to AACR April 2024","bullets":["Second enLIGHTEN platform candidate to be presented at AACR April 9, 2024; originally planned for Q3 2024.","First-in-class multimodal immunotherapy designed to induce tertiary lymphoid structures for solid tumors.","Abstract LB263; poster session on Tuesday April 9, 9:00 AM - 12:30 PM PT in San Diego.","Candidate follows Alpha 201-macro-1; data from preclinical models shown at SITC 2023 and Oncolytic Virus Conference 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-026877","json":"https://secwatch.observer/filing/0000950170-24-026877.json","markdown":"https://secwatch.observer/filing/0000950170-24-026877.md","text":"https://secwatch.observer/filing/0000950170-24-026877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024026877/0000950170-24-026877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024026877/cadl-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:54:54.161346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}